David A. Siegel Aurinia Pharmaceuticals Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 178,000 shares of AUPH stock, worth $2.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

178,000

Previous 128,000 39.06%

Holding current value

$2.11 Million

Previous $1.03 Million 46.45%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$7.2 - $8.64 $360,000 - $432,000	50,000 Added 39.06%	178,000 $1.51 Million
Q1 2025 May 15, 2025	BUY	$7.55 - $8.77 $966,400 - $1.12 Million	128,000 New	128,000 $1.03 Million
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $3.09 Million - $4.11 Million	-433,000 Reduced 74.28%	149,900 $1.35 Million
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $1.38 Million - $2.17 Million	-177,200 Reduced 23.31%	582,900 $4.53 Million
Q2 2023 Aug 14, 2023	BUY	$8.96 - $11.69 $4.23 Million - $5.52 Million	471,800 Added 163.65%	760,100 $7.36 Million
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $1.24 Million - $2.36 Million	209,100 Added 264.02%	288,300 $3.16 Million
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $61,650 - $122,100	15,000 Added 23.36%	79,200 $342,000
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $427,572 - $795,438	64,200 New	64,200 $483,000
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $734,992 - $911,640	-56,800 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$13.19 - $16.66 $400,976 - $506,464	-30,400 Reduced 34.86%	56,800 $837,000
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $189,208 - $245,621	13,400 Added 18.16%	87,200 $1.42 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $836,892 - $1.58 Million	73,800 New	73,800 $1.07 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $6.75 $65,945 - $73,575	-10,900 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $66,054 - $83,276	10,900 New	10,900 $71,000
Q3 2018 Nov 14, 2018	SELL	$5.27 - $6.64 $136,493 - $171,976	-25,900 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$5.06 - $6.36 $60,719 - $76,320	-12,000 Reduced 31.66%	25,900 $146,000
Q1 2018 May 15, 2018	SELL	$4.85 - $5.99 $50,924 - $62,895	-10,500 Reduced 21.69%	37,900 $197,000
Q4 2017 Feb 14, 2018	SELL	$4.53 - $7.09 $32,163 - $50,339	-7,100 Reduced 12.79%	48,400 $219,000
Q3 2017 Nov 14, 2017	BUY	$5.71 - $6.9 $316,905 - $382,950	55,500	55,500 $348,000

Others Institutions Holding AUPH

# of Institutions

245

Shares Held

62.5M

Call Options Held

1.03M

Put Options Held

666K

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.68B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account